AstraZeneca Starts AI Collaboration to Accelerate Drug Discovery
Pharmaceutical company AstraZeneca has initiated a long-term collaboration with BenevolentAI to leverage artificial intelligence and machine learning for the discovery of new treatments for chronic kidney disease and idiopathic pulmonary fibrosis.
Pharmaceutical giant AstraZeneca and UK-based artificial intelligence company BenevolentAI have commenced a long-term collaboration aimed at accelerating the discovery and development of new medicines. The partnership will utilize AI and machine learning, initially focusing on treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).
The collaboration involves scientists from both organizations combining AstraZeneca's extensive data assets, including genomics, chemistry, and clinical information, with BenevolentAI's target identification platform. This platform utilizes a vast biomedical knowledge graph to identify potential drug targets.
By systematically analyzing large datasets using machine learning, the companies aim to uncover the underlying biological mechanisms of complex diseases like CKD and IPF. This approach is expected to expedite the identification of novel therapeutic targets.
BenevolentAI is recognized for its AI-driven drug discovery solutions. Its Benevolent Platform assists researchers in identifying new pathways and mechanisms relevant to disease pathophysiology. The partnership seeks to address unmet medical needs in conditions lacking effective treatments.